Ovarian cancer trials in China

In China 184 Also abroad 795

184 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Huangpu District, Jinan, Linyi, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Neijiang, Shanghai, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Weifang, Wenzhou, Wuhan, Xinxiang, Xuzhou
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 1Taking people
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Where
Chengdu, Dalian, Fuzhou, Shanghai
Age
18 years and over
People
30
Run by
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
See details and how to joinNCT07923214
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changsha, Hangzhou, Shanghai
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Shanghai
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Lanzhou, Luoyang, Nanjing, Nanning, Shanghai, Shantou, Shenzhen, Tianjin, Wuhan
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 2Taking people
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Where
Beijing
Age
18 years and over
People
82
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07432594
Phase 3Taking people
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
Where
Beijing, Yunnan, Zhejiang
Age
18 years and over
People
420
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07779538
Phase 3Taking people
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Where
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xi’an, Zhengzhou
Age
18 years and over
People
82
Run by
Genmab
See details and how to joinNCT07604766
Phase 1/2Enrolling by invitation
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Where
Shenzhen
Age
10 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03393962
Phase 1Taking people
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
Where
Shanghai
Age
18 years and over
People
128
Run by
TJ Biopharma Co., Ltd.
See details and how to joinNCT07715747
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Where
Hefei
Age
18 years to 75 years
People
100
Run by
Anhui Provincial Hospital
See details and how to joinNCT06542549
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi’an, Yantai, Zhengzhou
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai, Tianjin, Wuhan, Xi’an
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1Taking people
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Where
Beijing
Age
18 years to 75 years
People
96
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06531486
No phaseTaking people
Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
Where
Guangzhou
Age
18 years to 75 years
People
40
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07895212
Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
Phase 1/2Taking people
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
Where
Shanghai
Age
18 years and over
People
150 worldwide
Run by
Phrontline Biopharma
See details and how to joinNCT07778498
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, Zhengzhou
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
No phaseTaking people
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT07760012
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 1/2Taking people
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Where
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
Age
18 years and over
People
233 worldwide
Run by
Ensem Therapeutics
See details and how to joinNCT06993844